Mesoblast (ASX:MSB) onboarded ten transplant centers in the US for the supply of Ryoncil for the treatment of steroid-refractory acute graft versus host disease during the March quarter, and the firm plans to recruit ten more priority transplant centers during the June quarter, according to a Wednesday Australian bourse filing.
The firm brought on board a team of nine key account managers in the last week of April, who will focus on onboarding the remaining 35 priority transplant centers, accounting for 80% of US pediatric transplants.
It also secured a Type B meeting with the US Food and Drug Administration scheduled for the June quarter to discuss the accelerated approval pathway for Revascor, a candidate for the treatment of patients with ischemic chronic heart failure with reduced ejection fraction and inflammation.
Its shares fell 2% in recent trading on Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。